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Modulation of cytosolic sexual steroid receptors in autochthonous
methylnitrosourea-induced rat mammary carcinoma following application
of 2-chloroethylnitrosocarbamoyl-L-alanine linked to oestradiol or
dihydrotestosterone
R. Corr, M.R. Berger, B. Betsch, J.A. Floride, H.P. Brix & D. Schmiahl
Institute ofToxicology and Chemotherapy, German Cancer Research Centre, Im Neuenheimer Feld280, D-6900 Heidelberg, FRG.
Summary This study concentrated on the influence of 2-chloroethylnitrosocarbamoyl-L-alanine (CNC-L-ala)
linked to oestradiol (CNA-L-ala-E2) or dihydrotestosterone (CNC-L-ala-DHT) in position 17 of the respective
steroid hormone on tumour growth and receptor kinetics of methylnitrosourea-induced rat mammary car-
cinoma. Both compounds almost completely arrested logarithmically growing mammary carcinoma of
Sprague-Dawley rats: in the first week CNC-L-ala-E2 blocked the growth of these tumours by 92% compared
to untreated control animals while, in animals treated with the physically equimolar mixture ofCNC-L-ala and
oestradiol (positive control), tumour growth was inhibited by 51% only. CNC-L-ala-DHT arrested the tumour
growth in the first week by 95%, while the respective positive control (CNC-L-ala plus dihydrotestosterone)
effected a growth inhibition of 71% compared to the untreated control. These results correlate well with the
influence of both drugs on the cytosolic receptor content of sexual steroid hormones in the tumours.
CNC-L-ala-E2 depleted the content of oestradiol receptors and kept it down for a week, while concomitantly
the content of progesterone receptors increased considerably and that of androgen receptors showed a
short-lived decrease. CNC-L-ala-DHT depleted androgen receptors as well as progesterone receptors. The
content of androgen receptors remained low for a week, while that of progesterone receptors recovered within
8 days. The content of oestrogen receptors showed a moderate decrease.
The average survival time of women suffering from metas-
tasising mammary carcinoma has been about 19 months for
more than 40 years (Patel et al., 1986; Petru & Schmiihl,
1987). None of the efforts made in mono- and combination
chemotherapy have been able to improve this parameter. For
this reason there is a basic need to find a more selective
therapy, capable of eliminating cancer cells more specifically
than conventional chemotherapy. The autochthonous rat
mammary carcinoma, induced by methylnitrosourea (MNU),
offers certain similarities to human premenopausal receptor-
positive breast cancer and therefore seems to be suited for
the preclinical evaluation of drugs against this type of cancer
(Wilkinson et al., 1986). The outlined strategy is based on the
presence of sexual steroid hormone receptors in 65-87%
(Eppenberger et al., 1979; Kimura, 1984; Longcope et al.,
1980; Mohammed et al., 1986) of human cancers and in 85%
(Ruzicka et al., 1980) of rat neoplasias. According to the
concept of Druckrey and Raabe (1952), an advantage in
terms of better targeting and higher therapeutic ratio is to be
obtained when a cytostatic agent binds more selectively to
tumour than to normal cells. In this study we investigated the
effects of the nitrosourea derivative 2-chloroethyl-
nitrosocarbamoyl-L-alanine (CNC-L-ala) linked to oestradiol
(E2) or dihydrotestosterone (DHT) in terms of antineoplastic
activity as well as receptor kinetics in MNU-induced receptor
positive rat mammary carcinoma.
Material and methods
Chemicals
Crystalline N-methyl-N-nitrosourea (MNU) was synthesised
by Dr M. Wiessler (Institute of Toxicology and Chemo-
therapy, German Cancer Research Center, Heidelberg).
MNU was dissolved at 1% in Sorensen buffer, pH6, and
distilled water (20/80, v/v). N-(2-chloroethyl)-N-nitroso-
carbamoyl-L-alanine (CNC-L-ala), N-(2-chloroethyl)-N-nitro-
socarbamoyl-L-alanine-oestradiol-17-ester (CNC-L-ala-E2)
and N-(2-chloroethyl)-N-nitrosocarbamoyl-L-alanine-dihydro-
testosterone-17-ester (CNC-L-ala-DHT) were synthesised
by Prof. Dr G. Eisenbrand. The structures of these com-
pounds are shown in Figure 1. CNC-L-ala, CNC-L-ala-E2
and CNC-L-ala-DHT were dissolved at 5% in DMSO.
Animals and tumour induction
Virgin female Sprague-Dawley (SD) rats (Institut fur Ver-
suchtierkunde, Hannover, FRG) were induced with MNU
and tumour bearing rats were treated as described by Berger
et al. (1986). The tumours were removed under slight ether
anaesthesia, shock-frozen in liquid nitrogen and then stored
at - 60°C for later hormone receptor determination.
Determination ofhormone receptors
The techniques were modified according to Agarwal (1983),
Tate and Jordan (1983), Moudgil (1983) and Norris (1983).
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All solutions were prepared in the following buffer: Tris/HCI,
pH 7.4, 40 mM, EDTA 1.5 mM, sodium azide 3 mM, dithio-
threitol 5 mM, sodium molybdate 10mM, methylphenylsul-
phonylfluoride 1 mm and glycerol 10%. The hormone
analogues moxestrol, methyltrienolone and promegestone
were purchased from New England Nuclear (Dreieich,
FRG). The compounds were stored in ethanol under nitro-
gen at - 20°C at a concentration of I tLM of the radioactive
and 1 mM of the non-radioactive compounds. One mM triam-
cinolone acetonide, purchased from Sigma (Munich, FRG),
was added to the radioactive methyltrienolone.
The frozen tumours were cooled in liquid nitrogen and
pulverised with a ball mill (type Micro-Dismembrator II,
Braun Melsungen, FRG). Two ml buffer was added to 1 g of
tissue powder and the suspension was homogenised with 10
strokes in a Dounce homogeniser. The homogenate was cen-
trifuged at 5,000g for 5 min, the pellet was homogenised
once more as before and the supernatants were collected. The
combined supernatants were centrifuged at 100,000g for 1 h
and the clear epiphase was taken for the cytosolic fraction.
The extract was stored for maximally 3 days at - 60°C.
The extract was diluted to 5 mg ml1' protein, as measured
by the Bio-Rad protein assay (Bio-Rad Laboratories GmbH,
Munich, FRG). Logarithmically decreasing concentrations of
radioactive hormone (highest concentration 30 nM) in a
volume of 0.1 ml were added to 0.1 ml extract and either
0.1 ml buffer or 0.1 ml non-radioactive hormone at 1,000-fold
higher concentrations than the radioactive agent. After
incubation for 2 h, 0.5 ml solution of 0.8% charcoal and
0.008% dextran 60 was added and incubated for 5 min. After
centrifugation at 1,000g for 5 min, 0.4 ml supernatant was
taken and the radioactivity was measured with 4 ml
Aqualuma (NEN, Dreieich, FRG) in a liquid scintillation
counter (Mark III, Searle). All steps were performed in dupli-
cate at + 4°C.
Our modification of the technique simplifies the method in
that three different hormone receptors are tested in one
optimised system instead of three different optimised solu-
tions. The results obtained were identical with those obtained
from unmodified methods. The measurement shows an excel-
lent linearity between the amount of steroid hormone recep-
tors and that of protein contained in the respective dilutions
(Figure 2). Linear extrapolation of the curve formed by the
relationship between protein and receptor content to zero
protein content, however, corresponds to negative receptor
levels. This implies that a certain low receptor content is
necessary to obtain measurable values.
Evaluation methods
Growth of tumours was monitored by recording tumour
number and tumour volume per animal. The total tumour
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Figure 2 Correlation of the receptor content determined in the
cytosol of mammary carcinoma cells with the respective protein
content. Symbols indicate the amount of progesterone, androgen,
and oestradiol receptors together with the respective standard
deviations (error bars).
volume per animal was calculated as the sum of all individual
tumours. Therapeutic efficacy was measured on the basis of
median total tumour volumes of treated groups vs controls
(T/C x 100).
Ranking criteria was chosen according to NCI recommend-
ations. Statistical significance was based on 95% confidence
limits of the median values per group. Additionally the
tumour volumes of the groups were compared by using a
non-parametric multivariate test according to Koziol and
Donna (1981). The survival times were compared according
to the Kruskal-Wallis test (Dunn, 1964).
For the graphical presentation of tumour growth the mean
tumour volume was expressed as a resultant of the initial
mean tumour volume plus the sum of the mean tumour
volume changes between the respective time intervals.
The evaluation of the receptor content was performed
according to the method of Scatchard (1949).
Results
The compounds CNC-L-ala-E2 and CNC-L-ala-DHT clearly
inhibited the growth of mammary tumours in SD rats
induced by methylnitrosourea. Figures 3 and 4 and Table I
show that the logarithmic growth of the tumours was less
delayed by the physical mixture of the cytotoxic agent CNC-
L-ala plus the respective hormone (positive control). Linking
CNC-L-ala to oestradiol or dihydrotestosterone yielded a
compound with stronger potency, probably also in com-
parison with the respective positive controls. The dihydrotest-
osterone derivative proved to be somewhat more active than
that of oestradiol. After the end of therapy the advantage of
the chemically linked derivatives was no longer detectable
due to regrowth of tumours.
The influence of CNC-L-ala-E2 on the cytosolic receptor
content of mammary tumours is shown in Figures 5-7. There
was a steep decrease of oestrogen receptors to barely detec-
table levels, which remained low for at least 4 days. The
amount of progesterone receptors had increased more than
twice after 48 h and then decreased to normal levels on day 8
after injection of the nitrosourea derivative. The content of
androgen receptors had decreased after 48 h and partly
replenished on day 8. The differential effect of CNC-L-ala-
DHT on oestrogen, progesterone and androgen receptors is
shown in Figures 8-10. This agent decreased the content of
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Figure 3 Mean tumour volume of methylnitrosourea-induced
mammary carcinoma in SD-rats following treatment with
75 Lrmol kg-i CNC-L-ala-oestradiol-17-ester in comparison to
positive (75prmolkg-' CNC-L-ala plus 75timolkg-' oestradiol)
and untreated controls. Treatment consisted of four injections,
respectively, which were given at days 1, 8, 22 and 29 after the
tumour burden per rat had reached a volume of 1 cm3. The
patterned areas represent the 95% confidence limits of the mean
tumour volume, respectively.44 R. CORR et al.
Table I Efficacy of N-(2-chloroethyl)-N-nitrosocarbamoyl-L-alanine-oestradiol-17-ester (CNC-L-ala-E2) and of N-(2-chloroethyl)-N-
nitrosocarbamoyl-L-alanine-dihydrotestosterone-17-ester (CNC-L-ala-DHT) in comparison with their unlinked single agents in MNU-induced
rat mammary carcinoma (dosage: 75pmolkg-', respectively)
TXT0 x ,ooa
No. of Cx-C. Median survival time
Group no. Treatment animals week I week S pb (95% conf. limits) %ILSe
I Control 1 20 68 (51-90)
II CNC-L-ala + E2 10 49 52 0.0060 35 (28-64) - 49
III CNC-L-ala-E2 10 8 14 0.OOOlC 80 (40-88) + 181
IV Control 2 20 76 (52-90)
V CNC-L-ala + DHT 10 29 63 0.0007 52 (19-85) - 32
VI CNC-L-ala-DHT 10 5 15 <O.OOOId 81 (63-160) + 79
aMean tumour volume of treated animals corrected for initial tumour volume in percent of the respective mean tumour volume of untreated
controls. bSignificance of tumour growth inhibition during the first 7 weeks versus untreated control according to the test of Koziol and Donna
(1981). CP = 0.019 significance of tumour growth inhibition during the first 7 weeks versus group II according to the test of Koziol and Donna.
dp = 0.096 significance of tumour growth inhibition during the first 7 weeks versus group V according to the test of Koziol and Donna.
'Increase in life span of treated animals over untreated controls. fP<0.01 versus group II. 'P<0.05 versus group V.
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Figure 4 Mean tumour volume of methylnitrosourea-induced
mammary carcinoma in SD rats following treatment with
75Imol kg-' CNC-L-ala-dihyrotestosterone- 17-ester in com-
parison to positive (751imolkg-' CNC-L-ala plus 75ILmolkg-'
dihydrotesterone) and untreated controls. The treatment regimen
consisted of four injections, respectively, which were given at
days 1, 8, 22 and 29 after the tumour burden per rat had reached
a volume of I cm3. The patterned areas represent the 95%
confidence limits of the mean tumour volume, respectively.
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Figure 5 Variation of cytosolic oestradiol receptor content ver-
sus time following a single i.p. injection of 75 gAmol kg- CNC-L-
ala-oestradiol-17-ester (time of injection = 0 h). The bars show
the standard deviation of six estimations.
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Figure 6 Variation of cytosolic progesterone receptor content
versus time following a single i.p. injection of 75 jimol kg-' CNC-
L-ala-oestradiol-17-ester (time of injection = 0 h). The bars show
the standard deviation of six estimations.
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Figure 7 Variation ofcytosolic androgen receptor content versus
time following a single i.p. injection of 75jsmol kg- I CNC-L-ala-
oestradiol-17-ester (time of injection = 0 h). The bars show the
standard deviation of six estimations.
androgen receptors for two days; partial replenishment could
be detected on day 8 (Figure 8). Interestingly, the content of
progesterone receptors also decreased initially. The decrease,
however, was not as steep as that of androgen receptors
(Figure 9). From the minimum found after 24 h replenishment
to normal levels occurred on day 8 after application of CNC-
L-ala-DHT. The influence of this agent on oestradiol receptors
is given in Figure 10. A moderate decrease was seen 24 h after
drug application, which reversed during the following 7 days.STEROID RECEPTOR KINETICS AFTER DRUG APPLICATION 45
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Figure 8 Variation of cytosolic androgen recept
time following a single i.p. injection of 75 lemol
dihydrotestosterone-17-ester (time of injection
show the standard deviation of six estimations
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Figure 9 Variation of cytosolic progesterone
versus time following a single i.p. injection of 75
L-ala-dihydrotestosterone-17-ester (time of injec
bars show the standard deviation of six estima
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Figure 10 Variation of cytosolic oestradiol rece
sus time following a single i.p. injection of 75 ltr
ala-dihydrotestosterone-17-ester (time of injec
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Discussion
This work is part of a comprehensive stud)
the pharmacokinetic and pharmacodynan
steroid-linked cytotoxic drugs. In this article
chemotherapeutic potential of CNC-L-ala-E2 and CNC-L-
ala-DHT as measured by their influence on tumour volume
and the possible mechanism of action as indicated by their
influence on measurable receptor contents in tumour cells. It
was demonstrated that both linked compounds inhibited the
growth of MNU-induced mammary carcinomas more than
the unlinked positive controls, as expected according to the
concept of Druckrey and Raabe (1952). The differences
observed (Figures 3 and 4), however, were significant for
CNC-L-ala-E2 only (P <0.02), and not for CNC-L-ala-DHT
(P<0.1) (Table I). The relatively low number of treated
animals, which was not sufficient to detect a significant
advantage of the latter compound, is due to the fact that
these groups belong to a comprehensive dose-response
study, which was (Berger et al., 1986) and will be detailed
elsewhere. 150 200 Both conjugates exerted some prolongation of life span
compared to untreated controls, which, however, was not
tor content versus significant due to the regrowth of tumours following therapy.
kg-' CNC-L-ala- The toxicity of the linked compounds was significantly lower
=Oh). The bars than that of the physical mixtures of CNC-L-ala and the
respective hormone as indicated by the median survival times
following administration of equimolar dosages (P = 0.03,
P <0.01) (Berger et al., 1984, 1986; Eisenbrand et al., 1988).
This is in line with experiments on bone marrow toxicity in
rats and mice: less suppression of bone marrow stem cell
colony formation was observed following administration of
the two linked agents compared to equimolar dosages of
CNC-L-ala (Berger et al., 1985; Eisenbrand et al., 1989).
These results demonstrate the possible therapeutic advantage
of linking a cytotoxic agent to a suitable carrier, here a I sexual steroid hormone.
The significantly altered pharmacodynamic activity of one
of the steroid-linked nitrosoureas can mainly be explained by
pharmacokinetic properties (Betsch et al., 1989). In com-
parison with the unlinked single agent CNC-L-ala the con-
jugate to oestradiol showed a three times faster tissue distri-
bution and a three-fold longer half-life in plasma (167 min).
150 200 In addition, the volume of distribution (2.36 litreskg-') of
the oestradiol-linked drug was three times larger than that of
receptor content CNC-L-ala, indicating a drug accumulation in certain body
pmol kg- CNC- compartments. Disposition studies showed that the intact
ction = 0 h). The oestradiol-linked drug could be detected in receptor contain-
ations. ing normal (uterus) and tumour (mammary carcinoma) tis-
sues at more than two times higher concentrations and over
five-fold longer periods of time than CNC-L-ala (Betsch et
al., 1990).
Compared to CNC-L-ala and its physical mixture with
oestradiol, CNC-L-ala-E2 showed also superior activity
against mammary carcinoma cells in vitro (Petru et al., 1988).
This is surprising because CNC-L-ala-E2 has a distinctly
lower halflife in vitro (t, = 24min in serum) than its parent
drug CNC-L-ala (t1 = 62min in serum) (Palm et al., 1989).
Studies on binding drugs to hormone receptors showed that
the linked compounds have some affinity to the hormone
receptors (up to 5% relative binding affinity of the respective
hormone; Berger et al., 1986; Eisenbrand et al., 1989). Cross-
affinity from CNC-L-ala-DHT-17-ester to the progesterone
receptor was also demonstrated (0.12%; Eisenbrand et al.,
1989). Determination of hormone receptor kinetics in this
study show that the conjugates specifically influence the
150 200 receptors. The influence of CNC-L-ala-E2 on progesterone
receptors resembles the physiological oestradiol influence
(Chico et al., 1984; Katzenellenbogen, 1980) whereas the
ptor content ver- protracted effect on oestradiol receptors contrasts to the
tion -Oh). The
quick replenishment of this receptor within 24h following tions=0h).
The administration of pure oestradiol (Katzenellenbogen, 1980). ations. Since the content of oestrogen receptors stayed low for at
least 8 days, the second injection of CNC-L-ala-E2 to mam-
mary carcinoma bearing rats was given to a tumour cell
population with low receptor content (Figure 3). This may be
the reason why the second application exhibited somewhat
concerned with reduced anti-tumour efficacy. The effects of CNC-L-ala-DHT
iic activities of on receptor contents, however, were partially reversible
we describe the within 8 days and this may be the reason why the second46 R. CORR et al.
application after 1 week prolonged the initially high
anti-neoplastic activity (Figure 4). The effects of CNC-L-ala-
DHT in comparison to dihydrotestosterone were unphysio-
logical to all three sexual steroid hormone receptors
(Katzenellenbogen, 1980). These results permit us to
hypothesise that the better anti-tumour activity of CNC-L-
ala-DHT compared to the E2-conjugate results from its more
severe disturbance of the physiological receptor kinetics.
Considering these observations and the facts that no
difference in anti-neoplastic activity between CNC-L-ala-E2
and the positive control was found in ovariectomised animals
as well as that CNC-L-ala alone exerts no influence on
steroid receptors (Berger et al., 1986), the anti-neoplastic
activity of the linked drugs probably was intensified by their
interaction with hormone receptors and the intracellular
effects thus originated.
The affinity of the conjugates to the receptors is by about
two orders of magnitude lower than that of the respective
physiological hormones. Relatively high concentrations ofthe
drugs are therefore needed to compete with physiological
hormone concentrations. Although the toxicity of the linked
compounds was lower than that of their positive controls,
their therapeutic ratio is still moderate. Nevertheless,
therapeutically active concentrations can be achieved in
receptor-positive tumour tissue (Betsch et al., 1990) and
reduced overall toxicity of the conjugates allows repeated
administrations within a reasonable period of time; both
properties represent discernible progress in the development
of targeting molecules and of nitrosoureas with increased
therapeutic ratio. Obviously, drugs with higher binding
affinity to the hormone receptors are needed, which will
allow further dose reduction due to more specific antineo-
plastic activity. Future studies will have to concentrate on
conjugates in which the moderately active cytotoxic moiety
CNC-L-ala (Klenner et al., 1989) has been replaced by more
active principles and on suited combinations of hormone-
linked cytotoxic agents, as well.
In summary, the data show that both linked compounds
were superior to their unlinked positive controls and their
efficacy was correlated with specific modulation of the recep-
tor contents. Although the higher anti-neoplastic activity and
lower toxicity observed resulted in higher therapeutic ratio,
the resulting anti-cancer potency might further be improved
by tailoring compounds with higher receptor affinity to the
target cells.
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